98%
921
2 minutes
20
The study aimed to develop a predictive model using machine learning algorithms, providing healthcare professionals with a novel tool for assessing disability risk in older adults. Data from the 2018 and 2020 waves of the China Health and Retirement Longitudinal Study were utilized, including 3,172 participants aged 65 years and older with no baseline disability. In this study, five machine learning algorithms were employed to construct risk assessment and prediction models for disability in older adults. The Shapley Additive Explanations method was applied to analyze the independent predictors of disability risk. In total, 695 participants (21.9%) were disabled during follow-up. Among the five machine learning models, prediction models constructed using random forest and extreme gradient boosting methods showed superior performance, achieving F1 scores of 0.92 and 0.86 and accuracies of 0.92 and 0.85, respectively. Key predictors of disability risk included self-rated health, education, sleep duration, alcohol consumption, depressive symptoms, hypertension, and arthritis. The Machine learning models for assessing and predicting disability risk in older adults, particularly those developed using RF and XGBoost algorithms, exhibited strong predictive capabilities. These findings highlight the potential of these models for practical application in clinical and public health settings, warranting further exploration and validation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064728 | PMC |
http://dx.doi.org/10.1038/s41598-025-01404-5 | DOI Listing |
JCO Oncol Pract
September 2025
Princess Margaret Cancer Centre, Toronto, Canada.
Purpose: To examine associations between special education, chronic health conditions (CHCs), and college graduation in survivors of childhood cancer and their siblings.
Methods: Childhood Cancer Survivor Study participants included 23,082 5-year survivors (53.7% male; median [IQR] age at diagnosis, 6 [3-13] years; age at evaluation, 31.
PLoS Negl Trop Dis
September 2025
Unit of Clinical and Molecular Medicine, ICMR-Vector Control Research Centre (VCRC), Indira Nagar, Puducherry, India.
Background: Filarial lymphedema, caused by lymphatic filariasis, is characterized by chronic swelling and recurrent skin infections. Acute adenolymphangitis (ADL) episodes significantly exacerbate morbidity. Diabetes mellitus (DM) increases susceptibility to infections; however, the relationship between diabetes and ADL frequency and severity in filarial lymphedema patients remains unclear.
View Article and Find Full Text PDFNeurol Sci
September 2025
School of Public Health, Shaanxi University of Chinese Medicine, Shaanxi, 712046, Xianyang, P. R. China.
Background: Stroke persists as the second leading global cause of mortality and disability. We analyzed G20 nations using Global Burden of Disease (GBD) 2021 data (1990-2021) to provide a new perspective.
Methods: We obtained age-standardized rates (ASR) of stroke mortality, incidence, prevalence, and YLLs (years of life lost) across G20 nations.
J Int Med Res
September 2025
Department of Orthopedics and Traumatology, Health Sciences University Fatih Sultan Mehmet Training and Research Hospital, Turkey.
ObjectiveTo determine the effectiveness of bilateral decompression combined with a unilateral transforaminal lumbar interbody fusion approach in centralizing a lordotic cage and preventing contralateral radiculopathy by ensuring equal foraminal elevation.MethodsThis is a retrospective cohort study based on clinical records and radiological data. Eighty-seven patients diagnosed with lumbar spinal stenosis at L3-S1 levels underwent bilateral decompression and transforaminal lumbar interbody fusion between 2017 and 2022.
View Article and Find Full Text PDFNeuropsychiatr Dis Treat
August 2025
Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA.
Brexpiprazole is a second-generation antipsychotic with multiple indications, including the treatment of schizophrenia. As a partial dopamine agonist, brexpiprazole differs from most other antipsychotics, yet uncertainties about its full mechanism of action have led to some ambiguity among prescribers. To address this gap, an international panel of psychiatric experts was organized and convened with funding from Otsuka Pharmaceutical Europe Ltd and H.
View Article and Find Full Text PDF